Physician profile
Muralidhar Pathikonda
NPI 1760677769
$6,882.75
in general payments reported to CMS, 2019-2025
37 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $113 · 2021: $379 · 2022: $1,131 · 2023: $1,184 · 2024: $1,736 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,746.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,385.50 | 2019-2025 | |
| Janssen Biotech, INC. | $687.07 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $373.20 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $360.36 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ethicon US, LLC | $350.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $327.12 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.67 | 2022-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $184.02 | 2024-2025 | Omvoh |
| Pfizer INC. | $154.50 | 2020-2025 | |
| Daiichi Sankyo INC. | $152.98 | 2019-2023 | Injectafer |
| Enterra Medical, INC. | $151.14 | 2024-2025 | |
| Medtronic, INC. | $146.38 | 2022 | |
| Ironwood Pharmaceuticals, INC | $127.22 | 2021-2023 | Linzess |
| Qol Medical, LLC | $126.24 | 2019-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $121.10 | 2025 | Zenpep |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $121.09 | 2025 | Voquezna |
| Gilead Sciences, INC. | $108.94 | 2024 | Vemlidy |
| Redhill Biopharma INC. | $103.94 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Merck Sharp & Dohme LLC | $85.22 | 2021-2024 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $77.99 | 2023-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $77.65 | 2019-2023 | Rebyota |
| Genzyme Corporation | $52.58 | 2024 | |
| Madrigal Pharmaceuticals | $45.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Fresenius Kabi USA, LLC | $37.83 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $34.16 | 2019-2023 | Suflave |
| Janssen Scientific Affairs, LLC | $33.23 | 2025 | Stelara, Tremfya |
| Nestle Healthcare Nutrition INC. | $28.44 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $27.28 | 2025 | Iqirvo |
| Vivus LLC | $26.73 | 2024 | Qsymia |
| Ardelyx, INC. | $24.94 | 2023 | Ibsrela |
| Organon LLC | $23.80 | 2022-2023 | Renflexis |
| Evoke Pharma, INC. | $21.22 | 2023 | Gimoti |
| Amgen INC. | $17.92 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.90 | 2025 | Givlaari |
| Shionogi INC | $15.71 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $13.66 | 2023 | Dat Closure Device |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,328.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muralidhar Pathikonda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.